XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
  Mental Health
  Aging
  Events
  Parenting
  Fitness
  Food & Nutrition
  Happiness
  Sleep Hygiene
  Occupational Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Health Channel
subscribe to Health newsletter

Medical News : Health

   DISCUSS   |   EMAIL   |   PRINT
The controversial history of Post-Menopausal Hormone Therapy
Feb 21, 2005, 00:03, Reviewed by: Dr.

�From a purely business point of view, the most reliable profits [for drug companies] can be made from disease processes and conditions that have high incidence and prevalence,�

 
There is a widespread controversy regarding the risks and benefits of hormone therapy (HT) for post-menopausal women with no end in sight. Roughly 45 million women in the US are post-menopausal and HT has been the predominant form of treatment for most of the twentieth century. But the history of these drugs (estrogen and estrogen plus progestin) illustrates a complex drama where different stakeholders with competing objectives can and did produce health practices and policies of questionable benefit. A critical analysis publishing in the recent issue of the Journal of Social Issues examines the back-story and key stakeholders�including the women who the authors say, �emerge as both willing participants and unwilling victims of the unintended consequences of these drugs.�

Post-menopausal HT began as, and is still prescribed as, a treatment to the severe to moderate symptoms that arise around menopause. It became a potential long-term therapy for the prevention and treatment of the most common causes of morbidity and mortality of women, e.g. heart disease, osteoporosis, and dementia�uses that were not approved by the FDA. But controlled studies found that there was no benefit for women�s health-related quality of life, but there was increased risk in breast cancer, increase in cardiovascular events and stroke risk among other results leaving the stakeholders in a dilemma. �From a purely business point of view, the most reliable profits [for drug companies] can be made from disease processes and conditions that have high incidence and prevalence,� the authors state. Post-menopausal symptoms provide drug companies such an opportunity, even for those with drugs that create positive results, i.e. prevent heart disease. For physicians their professional credibility is affected and for women it�s personal. HT once held the promise of regained femininity and the prolongation of youth- now it holds controversy.
 

- This study is published in the current issue of Journal of Social Issues
 

The Society for the Psychological Study of Social Issues.

 
Subscribe to Health Newsletter
E-mail Address:

 

This study is published in the current issue of Journal of Social Issues. For a PDF of this article please contact [email protected]

Journal of Social Issues brings behavioral and social science theory, empirical evidence, and practice to bear on human and social problems. Each issue of the journal focuses on a single topic - recent issues, for example, have addressed poverty, housing and health; privacy as a social and psychological concern; youth and violence; and the impact of social class on education. It is published on behalf of The Society for the Psychological Study of Social Issues.

Michelle Naughton is an Associate Professor in the Department of Public Health Sciences at the Wake Forest University School of Medicine. She is also a Co-Investigator of the Clinical Facilitation Center for the Women�s Health Initiative.


Related Health News

Mental health problems threaten the knowledge economy
Raine Study: Breastfeeding boosts mental health
The need for "exercise prescriptions."
Sleep-related breathing disorder can increase risk of depression
Mandarin oranges decrease liver cancer risk,atherosclerosis
The future of plastic surgery
Parents drink, Suffer the Children
University of Pittsburgh to host Global Health Conference
IOF to launch 'Bone App�tit' campaign on October 20
Online video games found to promote sociability


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us